NASDAQ · GRCE
Grace Therapeutics, Inc.
Healthcare · Biotechnology
$2.14▲ 0.94% ($0.02)today
As of 10:37 AM ET
Market cap
$34.83M
P/E
-1.70
EPS (TTM)
-$1.24
Next earnings
Nov 12, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $2.14 · Price Sep 24, 2:37 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 30.04% over the last year. Free cash flow grew 21.42% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Return analysis
Company profile
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada.
Market multiples
Stock splits
Every 6 shares became 1
Every 8 shares became 1
Every 10 shares became 1
Profitability & growth
Analyst consensus
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q4 FY26 · EPS est -$0.15 · Revenue est $1M
View
Institutional Sentiment
Grace Therapeutics, Inc. · GRCE
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.